Beta Bionics Funding & Investors
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.
betabionics.comTotal Amount Raised: $293,452,928
Beta Bionics Funding Rounds
Series D
$100,000,000
Series D Investors
Omega FundsSands Capital ManagementArrowMark PartnersEventide FenwayRTW InvestmentsSoleus CapitalFarallon Capital ManagementPerceptive AdvisorsPura Vida InvestmentsMarshall WaceLifeSci Venture PartnersSeries C
$57,000,000
Series C Investors
Eventide FenwayFarallon Capital ManagementPerceptive AdvisorsRTW InvestmentsSoleus CapitalPura Vida InvestmentsNovo NordiskLifeSci Venture PartnersArrowMark PartnersSeries B
$63,000,000
Series B Investors
Perceptive AdvisorsSoleus CapitalFarallon Capital ManagementArrowMark PartnersRTW InvestmentsEventide FenwaySeries B
$63,000,000
Series B Investors
Eventide FenwayRTW InvestmentsDexcomZealand Pharma ALifeSci Venture PartnersArrowMark PartnersGrant
$2,000,000
Grant Investors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Series Unknown
$2,452,916
Equity Crowdfunding
$1,000,000
Series A
$5,000,000
Series A Investors
Eli LillyNovo Nordisk
Funding info provided by Diffbot.